Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 21.
doi: 10.1111/jgh.70171. Online ahead of print.

Dynamic Predictors of Malignancy in Main Duct-Involved IPMN: The Critical Role of MPD Diameter Changes in a Multicenter Study

Seong Ji Choi  1 , Tae Hyeon Kim  2 , Tae Jun Song  3 , Hyung Ku Chon  2 , Jun Seong Hwang  4 , Min Jae Yang  5 , Jun-Ho Choi  6 , Ki Hyun Ryu  7 , Seong-Hun Kim  8 , Sang Hyub Lee  9 , Chang Min Cho  10 , Chang Hwan Park  11 , Hong Sik Lee  1 , Young Woo Choi  7 , Jong-Yeup Kim  12   13 , Dong Won Yang  14
Affiliations

Dynamic Predictors of Malignancy in Main Duct-Involved IPMN: The Critical Role of MPD Diameter Changes in a Multicenter Study

Seong Ji Choi et al. J Gastroenterol Hepatol. .

Abstract

Background and aim: Main pancreatic duct (MPD)-involved intraductal papillary mucinous neoplasms (IPMNs) carry a significant risk of malignant transformation. However, the long-term malignancy outcomes and the effects of dynamic changes in MPD diameter and other dynamic predictors remain poorly understood.

Methods: This multicenter retrospective cohort study included patients diagnosed with MPD-involved IPMNs between 2010 and 2023 at eight university hospitals in South Korea. All patients underwent surveillance every 6 to 12 months, which included clinical assessments, tumor marker testing, and imaging studies. Malignancy was confirmed through surgical pathology, endoscopic tissue acquisition, or evidence of radiologic progression.

Results: Among 168 patients, 30 (17.8%) developed malignancy during a median 4.0-year follow-up (IQR, 2.1-7.0), yielding an annual incidence of 4.5%. Cumulative incidences of malignancy were 7.7% at 2 years, 14.3% at 4 years, and 14.9% at 6 years. The strongest predictor of malignancy was an MPD growth rate ≥ 2 mm/year (odds ratio [OR]: 33.039, p < 0.001), which also remained significant in Cox regression (hazard ratio: 45.356, p < 0.001). The emergence of new worrisome features (OR: 3.849, p = 0.036) and high-risk stigmata (OR: 3.288, p = 0.036) were also associated with malignancy risk, though not independently significant in Cox regression.

Conclusions: Dynamic MPD monitoring is essential for assessing malignancy risk in patients with MPD-involved IPMN. An MPD growth rate of ≥ 2 mm/year was the strongest predictor of malignant transformation, underscoring the value of longitudinal surveillance over static MPD diameter thresholds. Patients with rapid MPD growth should be considered for early surgical intervention or intensified monitoring to improve clinical outcomes.

Keywords: high‐risk stigmata; intraductal papillary mucinous neoplasm; pancreatic duct; pancreatic malignancy; worrisome feature.

PubMed Disclaimer

References

    1. P. B. de Oliveira, A. Puchnick, J. Szejnfeld, and S. M. Goldman, “Prevalence of Incidental Pancreatic Cysts on 3 Tesla Magnetic Resonance,” PLoS ONE 10 (2015): e0121317, https://doi.org/10.1371/journal.pone.0121317.
    1. M. Tanaka, C. Fernandez‐Del Castillo, T. Kamisawa, et al., “Revisions of International Consensus Fukuoka Guidelines for the Management of IPMN of the Pancreas,” Pancreatology 17 (2017): 738–753, https://doi.org/10.1016/j.pan.2017.07.007.
    1. R. H. Hruban, K. Takaori, D. S. Klimstra, et al., “An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms,” American Journal of Surgical Pathology 28 (2004): 977–987, https://doi.org/10.1097/01.pas.0000126675.59108.80.
    1. European Study Group on Cystic Tumours of the Pancreas. European Evidence‐Based Guidelines on Pancreatic Cystic Neoplasms,” Gut 67 (2018): 789–804, https://doi.org/10.1136/gutjnl‐2018‐316027.
    1. T. Ohtsuka, C. Fernandez‐Del Castillo, T. Furukawa, et al., “International Evidence‐Based Kyoto Guidelines for the Management of Intraductal Papillary Mucinous Neoplasm of the Pancreas,” Pancreatology 24 (2024): 255–270, https://doi.org/10.1016/j.pan.2023.12.009.

LinkOut - more resources